Kowa Releases Top-line Results For Dyslipidemia Trial

Headquartered in Nagoya, Japan, Kowa has announced that the new data showed that Pitavastatin may provide a new treatment option for patients with dyslipidemia. It may also be useful for multiple medications, as evidenced by a study supporting pitavastatin’s potential for low drug-drug interaction.

An open-label add-on study was conducted to determine the potential for drug interaction following daily administration of pitavastatin 4mg on the steady-state pharmacodynamic (PD) and pharmacokinetic (PK) profiles of warfarin. The study was also meant to assess the safety and tolerability of coadministration of warfarin and pitavastatin in 24 healthy adult subjects.

The results of the study demonstrated that the steady-state PD and PK profiles of warfarin were unaffected by the coadministration of pitavastatin, and thus no significant drug-drug interaction was observed. In addition, pitavastatin 4mg in combination with warfarin was safe and well tolerated by healthy subjects, when compared with warfarin administration alone, said the company.